Management of Patients with Relapsed/Refractory Multiple Myeloma

Management of Patients with Relapsed/Refractory Multiple Myeloma

Elsevier CME Independent Conference Highlights from EBMT and EHA 2018*

*This webcast is not endorsed by the conference organizer. The Elsevier Office of Continuing Medical Education is an independent medical education company that provides clinical updates, analysis, and expert perspectives through conference-coverage educational programs.

In this CME-accredited webcast, three experts discuss the clinical implications of some of the latest important research on relapsed/refractory multiple myeloma (RRMM). The roundtable discussion covers new data presented at the 2018 annual meetings of the European Hematology Association (EHA) and the European Society for Blood and Marrow Transplantation (EBMT). The topics discussed include: unmet needs in the treatment of RRMM; new data on treatment strategies (including the roles of proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies); and emerging treatments, such as chimeric antigen receptor (CAR) T-cell therapies.

TARGET AUDIENCE

This activity has been designed to meet the educational needs of oncologists, hematologists, pathologists, and other healthcare professionals (HCPs) responsible for the diagnosis, treatment, or management of patients with RRMM.

EDUCATIONAL OBJECTIVES

After viewing this activity, participants will be better able to:

  1. Outline the importance of balance between high treatment responses and quality of life (QoL)
  2. Analyze the latest clinical trial data available for the treatment of RRMM with current, novel, and emerging treatments
  3. Optimally select RRMM patients eligible for current or novel treatment strategies and understand which patients are eligible for emerging treatments (when available)

FACULTY

Parameswaran Hari, MD, MRCP, MS (Chair)
Froedtert Cancer Center
Milwaukee, WI, USA
Jesús San Miguel, MD, PhD
Clínica Universidad de Navarra (CUN)
Pamplona (Navarra), Spain

Noopur Raje, MD
Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Boston, MA, USA

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this Continuing Medical Education (CME) activity:

Name of Faculty or Presenter

Relationship Identified With:

Parameswaran Hari, MD, MRCP, MS

Consultant/Advisor: Amgen Inc.; Celgene Corporation; Juno Pharmaceuticals; Kite Pharma Inc.; Takeda Pharmaceutical Company Limited

Grant/Research Support: Amgen Inc.; Celgene Corporation; Takeda Pharmaceutical Company Limited

Jesús San Miguel, MD, PhDConsultant/Advisor: Amgen, Inc.; Bristol-Myers Squibb Company; Celgene Corporation; F. Hoffmann-La Roche Ltd; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis AG; Sanofi; Takeda Pharmaceutical Company Limited
 
Noopur Raje, MDConsultant/Advisor: Amgen Inc.; Celgene Corporation; Millennium Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
 

Non-faculty: Cordelia Nagle; Elena Knoche, PhD; Marijke Verhaaf; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD hereby state that neither they nor their spouse/life partner have had any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from Amgen, Inc.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education and Ology Medical Education.

CME Credit (Physicians)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Ology Medical Education. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians. 

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu. Additional information on the process of converting AMA PRA Category 1 Credit™ to ECMECs® can be found at: www.eaccme.eu.

CME INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Ology Medical Education, and Amgen, Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Course opens: 
09/10/2018
Course expires: 
09/09/2019
Rating: 
0

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician

Accreditation Period

Course opens: 
09/10/2018
Course expires: 
09/09/2019
Please login or register to take this course.